Klin Farmakol Farm. 2019;33(3):25-28 | DOI: 10.36290/far.2019.020

High pressure as a side effect of drugs

Jana Gregorová1,2, Petra Holečková3,4
1 Oddělení klinické farmacie, Nemocnice Na Bulovce, Praha
2 Ústav aplikované farmacie, Farmaceutická fakulta VFU, Brno
3 Ústav radiační onkologie, Nemocnice Na Bulovce, Praha
4 1. lékařská fakulta UK, Praha

Drugs are often overlooked as the cause of secondary hypertension. Non-steroidal anti-inflammatory drugs – given regulatory for
long period, sex hormones – in higher doses than substitution, immunosuppressants − cyclosporine, antidepressants − venlafaxine,
glucocorticoids, mineralocorticoids themselves, and drugs that lead to their excess, and some antineoplastics are associated
with blood pressure elevation. The main focus of the paper will be on the mechanism by which vascular endothelial growth factor
pathway blockers interfere with the regulation of blood pressure.

Keywords: hypertension, drugs, side effect, mechanism of action

Published: October 28, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gregorová J, Holečková P. High pressure as a side effect of drugs. Klin Farmakol Farm. 2019;33(3):25-28. doi: 10.36290/far.2019.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J jr., Filipovský J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Hypertenze & KV Prevence.2018; 7(Suppl): 2-22.
    2. Lovell AR, Ernst ME. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. 2017; 19: 39. Go to original source... Go to PubMed...
    3. Salvetti M, Paini A, et al. Acute blood pressure elevation: Therapeutic approach. Pharmacological Research.2018; 130: 180-190. Go to original source... Go to PubMed...
    4. AISLP - 2019. 3.
    5. Sander GE. Secondary hypertension Drugs and herbal preparations that increase pressure. Journal of the American Society of Hypertension. 2014; 8(12): 946-948. Go to original source... Go to PubMed...
    6. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59(10): 502-508. Go to original source... Go to PubMed...
    7. Touyz RM, Lang NN, et al. Recent Advances in Hypertension and Cardiovascular toxicities with VEGF Inhibition. Hypertension. 2017; 70: 220-226. Go to original source...
    8. Touyz RM, Herrmann SMS, et al. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. Journal of the American Society of Hypertension. 2018; 12(6): 409-425. Go to original source... Go to PubMed...
    9. Agarwal M, Thareja N, et al. Tyrosine Kinase Inhibitor-Induced Hypertension. Curr Oncol Rep. 2018; 20(8): 65. Go to original source... Go to PubMed...
    10. Hayman SR, Leung N, et al. VEGF Inhibition, Hypertension, and Renal Toxicity Curr Oncol Rep. 2012 August; 14(4): 285-294. Go to original source... Go to PubMed...
    11. Maitland, ML, Kasza KL, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009; 15(19): 6250-6257. Go to original source... Go to PubMed...
    12. Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. Journal of Clinical Oncology. 2004; 22(14_suppl): 6098-6098. Go to original source...
    13. Isidori AM, Graziadio C, et al. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. Journal of Hypertension. 2015; 33: 44-60. Go to original source... Go to PubMed...
    14. Hattori T, Murase T, et al. Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. Nagoya J. Med. Sci. 2013; 75: 81-92.
    15. Eisen T, Sternberg CN, et al. Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. J Natl Cancer Inst 2012; 104: 93-113. Go to original source... Go to PubMed...
    16. Boughton Ch, Taylor D, et al. Mineralocorticoid hypertension and hypokalaemia induced by posaconazole. Endocrinol Diabetes Metab Case Rep. 2018; 17-0157. Go to original source... Go to PubMed...
    17. Auchusa RJ, Yub MK, et al. Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer. The Oncologist 2014; 19: 1231-1240. Go to original source... Go to PubMed...
    18. Grossman A, Messerli FH, et al. Drug induced hypertension - An unappreciated cause of secondary hypertension. European Journal of Pharmacology. 2015; 763: 15-22. Go to original source... Go to PubMed...
    19. Gyamlani G, Gerac SA.,Secondary Hypertension due to Drugs and Toxins. Southern Medical Journal. 2007; 7(100): 692-699. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.